Connor Clark & Lunn Investment Management Ltd. Cuts Stock Position in MiMedx Group, Inc. (NASDAQ:MDXG)

Connor Clark & Lunn Investment Management Ltd. cut its holdings in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 60.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 107,995 shares of the company’s stock after selling 164,405 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned about 0.07% of MiMedx Group worth $1,039,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Van ECK Associates Corp purchased a new stake in MiMedx Group during the fourth quarter worth about $40,000. Point72 DIFC Ltd increased its stake in shares of MiMedx Group by 127.6% during the third quarter. Point72 DIFC Ltd now owns 7,626 shares of the company’s stock worth $45,000 after buying an additional 4,275 shares during the period. Orion Capital Management LLC increased its stake in shares of MiMedx Group by 46.3% during the third quarter. Orion Capital Management LLC now owns 11,700 shares of the company’s stock worth $69,000 after buying an additional 3,700 shares during the period. SkyView Investment Advisors LLC increased its stake in shares of MiMedx Group by 30.0% during the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the company’s stock worth $77,000 after buying an additional 3,000 shares during the period. Finally, AlphaQuest LLC purchased a new stake in shares of MiMedx Group during the fourth quarter worth approximately $88,000. 79.15% of the stock is currently owned by hedge funds and other institutional investors.

MiMedx Group Stock Down 1.5 %

MDXG stock opened at $7.97 on Friday. The company’s 50 day moving average price is $8.39 and its 200 day moving average price is $7.84. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. MiMedx Group, Inc. has a fifty-two week low of $5.47 and a fifty-two week high of $10.14. The firm has a market capitalization of $1.17 billion, a price-to-earnings ratio of 14.49 and a beta of 1.97.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings results on Wednesday, February 26th. The company reported $0.07 EPS for the quarter, meeting the consensus estimate of $0.07. The company had revenue of $92.91 million for the quarter, compared to analyst estimates of $89.42 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. On average, equities research analysts anticipate that MiMedx Group, Inc. will post 0.3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $13.00 target price on shares of MiMedx Group in a research note on Thursday, February 27th.

Insider Buying and Selling at MiMedx Group

In other MiMedx Group news, insider Kimberly Maersk-Moller sold 4,106 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $7.89, for a total value of $32,396.34. Following the transaction, the insider now directly owns 310,836 shares in the company, valued at $2,452,496.04. This represents a 1.30 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO William Frank Iv Hulse sold 81,446 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $7.80, for a total transaction of $635,278.80. Following the transaction, the chief accounting officer now owns 494,774 shares in the company, valued at approximately $3,859,237.20. This trade represents a 14.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 144,018 shares of company stock worth $1,130,312 over the last three months. Insiders own 1.30% of the company’s stock.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.